Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)
China · Delayed Price · Currency is CNY 43.17
-0.32 (-0.74%)
Feb 13, 2026, 3:04 PM CST
SHE:300255 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 894.97 | 997.77 | 1,397 | 2,327 | 2,941 | 2,354 |
Other Revenue | 33.04 | 33.04 | 13.25 | 9.65 | 27.3 | 9.76 |
| 928.01 | 1,031 | 1,410 | 2,336 | 2,968 | 2,364 | |
Revenue Growth (YoY) | -12.02% | -26.92% | -39.63% | -21.29% | 25.56% | 14.11% |
Cost of Revenue | 867.7 | 937.35 | 1,733 | 1,315 | 1,246 | 743.43 |
Gross Profit | 60.31 | 93.46 | -322.77 | 1,021 | 1,722 | 1,620 |
Selling, General & Admin | 175.47 | 216.34 | 630.71 | 739.69 | 1,220 | 1,098 |
Research & Development | 48.32 | 47.19 | 158.82 | 145.01 | 150.63 | 127.54 |
Other Operating Expenses | 28.82 | 2.11 | 17.24 | 22.02 | 26.77 | 23.71 |
Operating Expenses | 252.55 | 272.24 | 822.15 | 913.23 | 1,398 | 1,252 |
Operating Income | -192.25 | -178.78 | -1,145 | 107.99 | 324.06 | 368.78 |
Interest Expense | -102.62 | -102.83 | -96.41 | -93.04 | -62.29 | -55.81 |
Interest & Investment Income | 37.56 | 37.02 | 1.85 | 1.99 | 1.3 | 1.64 |
Currency Exchange Gain (Loss) | 0.25 | 0.25 | 4.76 | 6.69 | -4.4 | -6.47 |
Other Non Operating Income (Expenses) | -44.88 | -15.36 | -13.67 | -12.8 | -10.13 | -8.99 |
EBT Excluding Unusual Items | -301.94 | -259.7 | -1,248 | 10.84 | 248.54 | 299.15 |
Impairment of Goodwill | - | - | -1.78 | -1.78 | - | - |
Gain (Loss) on Sale of Assets | -0.76 | -0.78 | -0 | -0.09 | -0.11 | -0.02 |
Asset Writedown | 11.74 | -1.3 | - | -0.27 | - | - |
Other Unusual Items | 5.04 | 4.7 | 18.49 | 9.41 | 11.98 | 2.42 |
Pretax Income | -285.91 | -257.08 | -1,232 | 18.12 | 260.41 | 301.56 |
Income Tax Expense | 7.3 | 6.95 | 16.46 | 7.96 | 29.15 | 50.42 |
Earnings From Continuing Operations | -293.21 | -264.03 | -1,248 | 10.16 | 231.26 | 251.14 |
Minority Interest in Earnings | -8.38 | 14.55 | 7.94 | 7.36 | 2.31 | 1.7 |
Net Income | -301.59 | -249.48 | -1,240 | 17.51 | 233.57 | 252.84 |
Net Income to Common | -301.59 | -249.48 | -1,240 | 17.51 | 233.57 | 252.84 |
Net Income Growth | - | - | - | -92.50% | -7.62% | 12.23% |
Shares Outstanding (Basic) | 1,049 | 924 | 919 | 876 | 934 | 936 |
Shares Outstanding (Diluted) | 1,049 | 924 | 919 | 876 | 934 | 936 |
Shares Change (YoY) | 35.95% | 0.58% | 4.91% | -6.27% | -0.23% | -0.24% |
EPS (Basic) | -0.29 | -0.27 | -1.35 | 0.02 | 0.25 | 0.27 |
EPS (Diluted) | -0.29 | -0.27 | -1.35 | 0.02 | 0.25 | 0.27 |
EPS Growth | - | - | - | -92.00% | -7.41% | 12.50% |
Free Cash Flow | -145.5 | -183.37 | -205.6 | -428.1 | -305.21 | -383.36 |
Free Cash Flow Per Share | -0.14 | -0.20 | -0.22 | -0.49 | -0.33 | -0.41 |
Dividend Per Share | - | - | - | 0.005 | 0.026 | - |
Dividend Growth | - | - | - | -80.77% | - | - |
Gross Margin | 6.50% | 9.07% | -22.88% | 43.71% | 58.01% | 68.55% |
Operating Margin | -20.72% | -17.34% | -81.17% | 4.62% | 10.92% | 15.60% |
Profit Margin | -32.50% | -24.20% | -87.93% | 0.75% | 7.87% | 10.70% |
Free Cash Flow Margin | -15.68% | -17.79% | -14.58% | -18.32% | -10.28% | -16.22% |
EBITDA | -122.1 | -106.82 | -1,071 | 164.93 | 379.86 | 424.06 |
EBITDA Margin | -13.16% | -10.36% | -75.90% | 7.06% | 12.80% | 17.94% |
D&A For EBITDA | 70.15 | 71.96 | 74.39 | 56.94 | 55.8 | 55.28 |
EBIT | -192.25 | -178.78 | -1,145 | 107.99 | 324.06 | 368.78 |
EBIT Margin | -20.72% | -17.34% | -81.17% | 4.62% | 10.92% | 15.60% |
Effective Tax Rate | - | - | - | 43.94% | 11.19% | 16.72% |
Revenue as Reported | 928.01 | 1,031 | 1,410 | 2,336 | 2,968 | 2,364 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.